SAGE THERAPEUTICS INC (SAGE) Stock Analyst Ratings
USA - NASDAQ:SAGE - US78667J1088 - Common Stock
8.68 USD
-0.02 (-0.23%)
8.685 USD
+0.01 (+0.06%)
ChartMill assigns a Buy % Consensus number of 69% to SAGE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.67. This target is -0.09% below the current price.
SAGE was analyzed by 17 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about SAGE.
In the previous month the buy percentage consensus was at a similar level.
SAGE was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-08 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-06-20 | Baird | Maintains | Neutral -> Neutral |
| 2025-06-17 | Truist Securities | Maintains | Hold -> Hold |
| 2025-06-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-06-17 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-06-16 | Needham | Reiterate | Hold -> Hold |
| 2025-04-30 | Needham | Reiterate | Hold -> Hold |
| 2025-04-25 | Needham | Reiterate | Hold -> Hold |
| 2025-02-12 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-12 | Needham | Reiterate | Hold -> Hold |
| 2025-02-12 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-02-12 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-01-02 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-16 | Stifel | Maintains | Hold -> Hold |
| 2024-11-21 | TD Cowen | Maintains | Hold -> Hold |
| 2024-11-21 | RBC Capital | Upgrade | Underperform -> Sector Perform |
| 2024-11-20 | Needham | Reiterate | Hold |
| 2024-11-20 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-30 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-10-30 | Needham | Reiterate | Hold |
| 2024-10-30 | Oppenheimer | Maintains | Perform -> Perform |
| 2024-10-30 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-30 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-10-30 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-10-17 | Needham | Reiterate | Hold |
| 2024-10-10 | Raymond James | Reiterate | Market Perform |
| 2024-10-09 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-10-09 | Baird | Maintains | Neutral -> Neutral |
SAGE THERAPEUTICS INC / SAGE FAQ
What do analysts expect the price target to be for SAGE THERAPEUTICS INC (SAGE)?
17 analysts have analysed SAGE and the average price target is 8.67 USD. This implies a price decrease of -0.09% is expected in the next year compared to the current price of 8.68.
How do analysts rate SAGE THERAPEUTICS INC (SAGE)?
The consensus rating for SAGE THERAPEUTICS INC (SAGE) is 69.4118 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for SAGE THERAPEUTICS INC stock?
The number of analysts covering SAGE THERAPEUTICS INC (SAGE) is 17.